HHS Secretary Robert F. Kennedy Jr. said that the FDA would look for ways to fast-track approval for rare disease treatments ...

Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 ...

The Treasurer's Office said in a news release Thursday that 18 months of contract negotiations have resulted in “an untenable impasse" with CVS Caremark, "which potentially endangers the financial wel ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the ...

CVS is investing $20 billion in 10 years to help upgrade the consumer healthcare experience in what it hopes will be a ...

Omada Health went public on the Nasdaq Friday, marking the second digital health company to do so after a post-pandemic drought.

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

The pharmacy giant manages the prescription drug benefit for the State Health Plan, but contract negotiations are at an impasse.

Another challenge is brewing for restaurants. It’s not the economy, another global disease, or a weather disaster. It’s the ...